ImmunityBioIBRX
IBRX
About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Employees: 685
0
Funds holding %
of 7,430 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
168% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 37
131% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 26
35% more capital invested
Capital invested by funds: $239M [Q1] → $322M (+$82.9M) [Q2]
13% more funds holding
Funds holding: 208 [Q1] → 235 (+27) [Q2]
4.5% more ownership
Funds ownership: 9.32% [Q1] → 13.82% (+4.5%) [Q2]
4% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $9.87M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
239%
upside
Avg. target
$16
578%
upside
High target
$24
917%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 917%upside $24 | Buy Maintained | 19 Aug 2025 |
HC Wainwright & Co. Andres Maldonado | 239%upside $8 | Buy Reiterated | 4 Jun 2025 |
Financial journalist opinion
Based on 7 articles about IBRX published over the past 30 days
Neutral
Business Wire
2 hours ago
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with its investigational immune-boosting regimen including ANKTIVA® (nogapendekin alfa inbakicept-pmln) in this pilot study (NCT06061809). All five patients achieved 100% disease control with the regimen that combines ANKTIVA, an IL-15 agonist being studied for its ability to enhance natural killer (NK.
Neutral
Business Wire
1 week ago
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient's quality of life. Long COVID remains a signifi.
Neutral
Business Wire
1 week ago
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete responses in the first two patients treated to date with late-stage Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. QUILT-106 (NCT06334991) is a first-in-human trial evaluating the safety and preliminary efficac.
Neutral
Business Wire
2 weeks ago
ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Houston recently became the first VA hospital in the Houston region and one of the first in the U.S. to provide treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) to a veteran with bladder cancer. ANKTIVA, the first of its kind immune-boosting, lymphocyte stimulating agent, is approved by th.
Positive
The Motley Fool
2 weeks ago
IBRX Sales Soar 2,540%
ImmunityBio (IBRX -0.21%), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating analyst GAAP revenue estimates of $23.15 million, as commercial sales of the immunotherapy ANKTIVA accelerated.
Neutral
Zacks Investment Research
3 weeks ago
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
Neutral
Business Wire
3 weeks ago
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and six months ended June 30, 2025. In the second quarter of 2025, ImmunityBio reported $26.4 million in revenue, representing a 60% increase from $16.5 million in the first quarter of 2025. This growth reflects continued commercial traction of ANKTIVA in combination with BCG in BCG-unresponsive NMIBC with carcinoma in situ (CIS) w.
Neutral
Business Wire
1 month ago
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of Immunity.
Neutral
Business Wire
1 month ago
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced preliminary financial results for the fiscal quarter ended June 30, 2025, and clinical progress across its pipeline. Key Highlights Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of ~$43 million. ANKTIVA® Unit Growth Since J-Code: 246% unit sales volume growth in 1H 2025 compared to 2H 2024. Cash Positi.
Neutral
Seeking Alpha
1 month ago
ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval
Recent ASCO data and UK MHRA approval for ANKTIVA reinforce my bullish thesis, despite the FDA's Refusal to File setback. ANKTIVA's potential to reverse lymphopenia in late-stage cancer patients could open significant new markets beyond bladder cancer. Major risks remain: FDA's RTF for sBLA and ImmunityBio's concerning cash position increase the likelihood of dilution.
Charts implemented using Lightweight Charts™